FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
15/03/2025
Voltar para busca
Dado oficial do USPTO
ZORYA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
16/03/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 42
Data de depósito
07/12/2022
Data de registro
27/08/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/08/2024
Última transação
16/03/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
FR
Examinador
ROTH, BENJAMIN
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
CYTOO
Representantes
Steven J. Solomon Tucker Ellis LLP
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical productsnamely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases; Veterinary productsnamely veterinary preparations for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases; Sanitary products for medicinenamely sanitary preparations for medical use; Chemical and biological preparations for medical usenamely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases; chemical and biological preparations for pharmaceutical use for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases
Classe 9
Quality control and testing devices namely culture plates to test and conduct quality control in the field of biologybiotechnology and pharmacy; downloadable software for the collectionprocessing and analysis of data in the field of biotechnology and pharmacy; scientific laboratory instrumentsnamely computer hardware and downloadable software for data analysisdatabase managementdata processingin the field of life science research and the pharmaceutical industry market and diagnostics
Classe 42
Medicalbiotechnologicalpharmaceutical research; research and development of chemicalbiological and scientific products and materials in the biologicalbiotechnologicalmedicaldiagnostic and pharmaceutical fields; scientific researchadvisory and information services in the medicalbiotechnologicalpharmaceuticaldiagnostictechnological and industrial fields; design and development of computerssoftware and computer platforms; technical testing namely technological testing in the scientificbiologicalbiotechnological and medical fields and quality control services of goods and services; advisory services with respect to quality testingtechnical testing namelytechnological testing in the scientificbiologicalbiotechnological and medical fields and scientific and medical clinical trials; services for scientific development and analysis of cell tests; scientific and medical research and development of products and services in the field of imagingin the scientificbiologicalbiochemicalmolecular-biologybiotechnological and medical fields; Scientific interpretation and analysis of data by imaging in the scientificbiologicalbiochemicalmolecular-biologybiotechnological and medical fields; diagnostic and industrial research in the biologicalbiotechnological and medical fields
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
22/02/2025
FIMP
FINAL DISPOSITION PROCESSED
21/02/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/11/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
27/08/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
27/08/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/06/2024
PUBO
PUBLISHED FOR OPPOSITION
11/06/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/05/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/05/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/05/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/05/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/05/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/05/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/05/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
06/05/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/05/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
06/05/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/04/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/04/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/04/2024
RFNT
REFUSAL PROCESSED BY IB
25/10/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/10/2023
RFRR
REFUSAL PROCESSED BY MPU
04/10/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
25/09/2023
CNRT
NON-FINAL ACTION WRITTEN
24/09/2023
DOCK
ASSIGNED TO EXAMINER
13/09/2023
MAFR
APPLICATION FILING RECEIPT MAILED
16/06/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/06/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/06/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ZORYA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.